Abstract:BACKGROUND:Both pharmacologic and genetic approaches have been used to study the involvement of the muscarinic acetylcholine system in the regulation of chronic pain. Previous studies suggest that the M2 and M4 subtypes of muscarinic acetylcholine receptors (mAChRs) are important targets for the development of chronic pain. (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] octane (PTAC) has agonist effects on muscarinic M2 and M4 receptors and antagonist effects on muscarinic M1, M3, and M5 receptors. However, its analgesic effects have been less studied. METHODS:Male C57B L/6 mice were anesthetized, and left common peroneal nerve (CPN) ligation was performed to induce neuropathic pain. Before and after the application of PTAC systemically or specifically to the anterior cingulate cortex (ACC), the withdrawal thresholds to mechanical stimulation and static weight balance were measured, and the effects of PTAC on the conditioned place preference (CPP) were further evaluated. Western blotting was used to examine the expression of M1 and M2 in the striatum, ACC, and ventral tegmental area. RESULTS:The application of PTAC ([i.p.] intraperitoneal injection) increased the paw withdraw threshold in both the early (0.05 mg/kg, mean difference [95% confidence interval, CI]: 0.19 [0.05-0.32]; 0.10 mg/kg: mean difference [95% CI]: 0.34 [0.22-0.46]) and the late phases (0.05 mg/kg: mean difference [95% CI]: 0.45 [0.39-0.50]; 0.1 mg/kg: mean difference [95% CI]: 0.44 [0.37-0.51]) after nerve injury and rebalanced the weight distribution on the hind paws of mice (L/R ratio: before, 0.56 ± 0.03. 0.05 mg/kg, 1.00 ± 0.04, 0.10 mg/kg, 0.99 ± 0.03); however, it failed to induce place preference in the CPP (0.05 mg/kg, 2-way analysis of variance, P > .05; 0.2 mg/kg, 2-way analysis of variance, P > .05,). At the same doses, the analgesic effects at D3-5 lasted longer than the effects at D14-16. This may be due to the down-regulation of the M2 and M1 in tested brain regions. CONCLUSIONS:These observations suggested that PTAC has analgesic effects on the neuropathic pain induced by nerve injury.

Nicotine Inhibits Rapamycin-Induced Pain Through Activating Mtorc1/s6k/irs-1-related Feedback Inhibition Loop

Nicotine inhibits rapamycin-induced pain through activating mTORC1/S6K/IRS-1-related feedback inhibition loop.

Nicotine Decreases Nerve Regeneration and Pain Behaviors Via PTEN and Downstream Inflammation-Related Pathway in Two Rat Nerve Injury Models.

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

Effects of Intrathecal Injection Rapamycin on Neuropathic Pain Behaviors in Mice

The Mammalian Target of Rapamycin Pathway in the Basolateral Amygdala is Critical for Nicotine-Induced Behavioural Sensitization.

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Targeting spinal mechanistic target of rapamycin complex 2 alleviates inflammatory and neuropathic pain

Pharmacological Modulation of the MIP-1 Family and Their Receptors Reduces Neuropathic Pain Symptoms and Influences Morphine Analgesia: Evidence from a Mouse Model

Intrathecal rapamycin attenuates the mechanical hyperalgesia of paclitaxel-induced peripheral neuropathy in mice

Rapamycin Suppresses Microglial Activation and Reduces the Development of Neuropathic Pain after Spinal Cord Injury.

Augmenting the antinociceptive effects of nicotinic acetylcholine receptor activity through lynx1 modulation

Activation of mTOR in the spinal cord is required for pain hypersensitivity induced by chronic constriction injury in mice.

Chronic Nicotine Exposure Elicits Pain Hypersensitivity Through Activation of Dopaminergic Projections to Anterior Cingulate Cortex.

Mtor Pathway is Involved in Adp-Evoked Astrocyte Activation and Atp Release in the Spinal Dorsal Horn in A Rat Neuropathic Pain Model

α4 nicotinic receptors on GABAergic neurons mediate a cholinergic analgesic circuit in the substantia nigra pars reticulata

Small G-Protein Rheb Gates Mammalian Target of Rapamycin Signaling to Regulate Morphine Tolerance in Mice.

Spinal SIRT1 Activation Attenuates Neuropathic Pain in Mice

Role of mammlian target of rapamycin signaling pathway in spinal cord in development of neuropathic pain in rats

NAMPT/NAD+/PARP1 Pathway Regulates CFA-Induced Inflammatory Pain via NF-κB Signaling in Rodents

Mtor-Neuropeptide Y Signaling Sensitizes Nociceptors to Drive Neuropathic Pain